PEREGRINE PHARMACEUTICALS PRESENTS TARVACIN DATA

Peregrine presented new data at the Biotechnology Industry Organization 2005 (BIO 2005) annual meeting in Philadelphia, Pa., supporting the broad anti-viral potential of Tarvacin.

The data presented at BIO 2005 showed that Tarvacin binds to enveloped virus particles representing six different virus families, binds to virally infected cells and inhibits viral replication in multiple virus systems. The data also indicated that Tarvacin provided significant protection against Cytomegalovirus and Pichinde virus (an in vivo Lassa fever model) infections.

Data presented at the conference demonstrated: Tarvacin binds to viruses from six different enveloped virus families, including specific binding to HIV 1 and 2, Influenza A and B, Measles, Respiratory Syncitial Virus (RSV), Bovine Viral Diarrhea (a surrogate in vitro Hepatitis C virus model), and Pichinde virus.

Tarvacin binds to cells infected with Influenza, Vaccinia (a model for Smallpox) and Pichinde viruses. Anti-Phosphatidylserine antibodies inhibited replication of RSV, Vesicular Stomatitis Virus and Pichinde viruses. Anti-Phosphatidylserine antibodies provided significant protection in animals infected with cytomegalovirus with 100 percent of the Anti-Phosphatidylserine antibodies treated animals surviving and only 20 percent of animals receiving control treatment surviving.

Tarvacin provided significant protection in animals administered lethal viral loads of Pichinde virus (a model of Lassa fever) with 50 percent of the Tarvacin treated animals surviving and none of the animals receiving control treatment surviving. Animals lethally infected with Pichinde virus that survived following Tarvacin therapy had long-term immunity to reinfection.